NephroGenex registers $34.5 million of its stock for a public offering

Bookrunners Canaccord Genuity and JMP Securities will assist with sale

By Devika Patel

Knoxville, Tenn., April 20 – NephroGenex, Inc. will price a public sale of common stock with a 30-day greenshoe, according to a Form S-1 filed Monday with the Securities and Exchange Commission. The company has registered up to $34.5 million of stock.

Canaccord Genuity and JMP Securities are the bookrunning managers.

Proceeds will be used for clinical development, working capital and general corporate purposes.

The Research Triangle Park, N.C., pharmaceutical company develops therapeutics to treat kidney disease.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.